Drug intelligence / Profile preview

Bailing Tongfengxiao Granules

Development stage: Unknown
Lead developer: Guangzhou Fan Houtang Pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

Bailing Tongfengxiao Granules is a traditional Chinese medicine (TCM) formulation developed by Guangzhou Fan Houtang Pharmaceutical Technology Co., Ltd. for the treatment of acute gouty arthritis. It is specifically indicated for the 'damp-heat stasis syndrome' (湿热瘀阻证), a TCM classification characterized by joint redness, swelling, and heat. The formulation is designed to provide anti-inflammatory and analgesic effects during acute gout flares. Clinical development has included Phase 2 trials (such as CTR20210087) focused on dose exploration and preliminary efficacy and safety assessment.

Brand names: Bailing Tongfengxiao Granules
Other names: 百苓痛风消颗粒

Beyond the preview

Go deeper on Bailing Tongfengxiao Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bailing Tongfengxiao Granules.

Explore the full profile